TLR2 and acute kidney injury: The extent of AKI was not different between CDDP-treated WT recipients of TLR-2-primed WT and Gal-3-/-macrophages (Figure S1), suggesting that genetic deletion of Gal-3 did not affect immunomodulatory capacity of TLR-2-activated macrophages.